Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 774 | 6.85 |
09:41 ET | 284 | 6.835 |
09:43 ET | 600 | 6.88 |
09:50 ET | 455 | 6.92 |
09:52 ET | 2900 | 6.99 |
09:56 ET | 1117 | 7.02 |
09:57 ET | 1410 | 7.065 |
09:59 ET | 200 | 7.07 |
10:01 ET | 443 | 7.0719 |
10:03 ET | 200 | 7.08 |
10:08 ET | 200 | 7.045 |
10:15 ET | 300 | 7.09 |
10:17 ET | 600 | 7.11 |
10:21 ET | 100 | 7.14 |
10:24 ET | 500 | 7.09 |
10:26 ET | 400 | 7.15 |
10:30 ET | 300 | 7.15 |
10:32 ET | 450 | 7.125 |
10:33 ET | 380 | 7.125 |
10:35 ET | 1105 | 7.095 |
10:44 ET | 600 | 7.085 |
10:48 ET | 1000 | 7.08 |
10:50 ET | 200 | 7.065 |
10:51 ET | 244 | 7.055 |
10:53 ET | 200 | 7.03 |
11:00 ET | 200 | 7.01 |
11:02 ET | 200 | 7.015 |
11:04 ET | 100 | 7.02 |
11:11 ET | 200 | 7.01 |
11:13 ET | 300 | 7.035 |
11:15 ET | 1200 | 7.07 |
11:20 ET | 500 | 7.07 |
11:26 ET | 700 | 7.065 |
11:29 ET | 300 | 7.075 |
11:31 ET | 502 | 7.07 |
11:36 ET | 300 | 7.04 |
11:40 ET | 100 | 7.03 |
11:42 ET | 200 | 7.03 |
11:44 ET | 100 | 7.01 |
11:45 ET | 898 | 7 |
11:47 ET | 225 | 7.03 |
11:51 ET | 100 | 7.03 |
12:03 ET | 450 | 7.01 |
12:05 ET | 700 | 7.035 |
12:09 ET | 100 | 7.07 |
12:16 ET | 281 | 7.07 |
12:21 ET | 1346 | 7.06 |
12:27 ET | 500 | 7.1 |
12:30 ET | 823 | 7.1 |
12:32 ET | 700 | 7.1 |
12:34 ET | 100 | 7.1 |
12:36 ET | 200 | 7.08 |
12:38 ET | 2235 | 7.12 |
12:41 ET | 1930 | 7.125 |
12:43 ET | 100 | 7.125 |
12:45 ET | 100 | 7.14 |
12:48 ET | 100 | 7.14 |
12:52 ET | 100 | 7.135 |
12:54 ET | 200 | 7.135 |
12:56 ET | 1820 | 7.135 |
12:57 ET | 3893 | 7.12 |
12:59 ET | 20281 | 7.13 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 148.0M | -0.7x | --- |
Adlai Nortye Ltd | 134.3M | -0.5x | --- |
Elevation Oncology Inc | 147.5M | -2.6x | --- |
Vigil Neuroscience Inc | 148.5M | -1.9x | --- |
Atossa Therapeutics Inc | 147.1M | -5.0x | --- |
bluebird bio Inc | 174.0M | -1.2x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $148.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.